Smoldering multiple myeloma (SMM)

طلب موعد

Survival rates

There is no single 5-year or 10-year survival rate for everyone with SMM. Survival depends on factors such as age, overall health, risk level, treatment and whether SMM progresses to active multiple myeloma.

In a phase 3 study of people with high-risk SMM:

  • 93% of people who received daratumumab were alive after 5 years.
  • 86.9% of people who had active monitoring were alive after 5 years.

These results apply only to people who met the study’s requirements. They cannot predict what will happen to one person.

A separate review looked at how often SMM progressed to active multiple myeloma. By 10 years, about 60% of people across all risk groups had progression. Among people with high-risk SMM, about 86% had progression.

If SMM progresses, it becomes active multiple myeloma. Then, a person's outlook depends on factors such as age, overall health and treatment.

طلب تحديد موعد
Stagesالأطباء والأقسام
15/08/2026

Living with smoldering multiple myeloma (SMM)?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

shenriq
Essential Thrombocythemia: Looking for information and support

711 Replies Sun, Sep 06, 2026

hikerny
Anyone have chronic lymphocytic leukemia (CLL)?

377 Replies Sat, Sep 05, 2026

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

921 Replies Wed, Sep 02, 2026

See more discussions
  1. Multiple myeloma. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed August 4, 2026.
  2. Kumar SK, et al. Multiple myeloma, version 5.2026, NCCN Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0001.
  3. Zanwar S, et al. Diagnosis, risk stratification and management of smouldering multiple myeloma. Nature Reviews Clinical Oncology. 2026; doi:10.1038/s41571-026-01119-0.
  4. Mateos MV, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal. 2020; doi:10.1038/s41408-020-00366-3.
  5. Chabrun F, et al. Enhanced dynamic risk stratification of smoldering multiple myeloma. Nature Medicine. 2026; doi:10.1038/s41591-026-04304-x.
  6. Ludwig H, et al. Temporal trends in progression risk in smoldering myeloma: A systematic review. eClinicalMedicine. 2026; doi:10.1016/j.eclinm.2025.103750.
  7. Sandecka V, et al. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00906-7.
  8. Ntanasis-Stathopoulos I, et al. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01312-x.
  9. Dimopoulos MA, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. New England Journal of Medicine. 2025; doi:10.1056/NEJMoa2409029. Erratum published 2026.
  10. U.S. Food and Drug Administration. FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma. Accessed August 4, 2026.

Smoldering multiple myeloma (SMM)